Exosite-driven substrate specificity and function in coagulation

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 1, 2005, Pages 54-67

  Krishnaswamy, S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Blood coagulation; Enzymology; Macromolecular substrate specificity; Serine proteinases

Indexed keywords

BLOOD CLOTTING FACTOR 10A; PROTHROMBIN; SERINE PROTEINASE; THROMBOPLASTIN;

BLOOD CLOTTING; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYMOLOGY; HEMOSTASIS; KINETICS; MACROMOLECULE; PRIORITY JOURNAL; REVIEW; ANIMAL; BINDING SITE; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN;

ANIMALS; BINDING SITES; BLOOD COAGULATION; HUMANS; KINETICS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTHROMBIN; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY; THROMBOPLASTIN;

EID: 17644371341     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01021.x     Document Type: Review

References (115)

1. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915-56.
2. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
3. Neurath H. Evolution of proteolytic enzymes. Science 1984; 224: 350-7.
4. Neurath H. The versatility of proteolytic enzymes. J Cell Biochem 1986; 32: 35-49.
5. Rawlings ND, Barrett AJ. Evolutionary families of peptidases. Biochem J 1993; 290: 205-18.
6. Krem MM, Rose T, Di Cera E. Sequence determinants of function and evolution in serine proteases. Trends Cardiovasc Med 2000; 10: 171-6.
7. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
8. Roach JC, Wang K, Gan L, Hood L. The molecular evolution of the vertebrate trypsinogens. J Mol Evol 1997; 45: 640-52.
9. Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997; 272: 29987-90.
10. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995; 4: 337-60.
11. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27: 157-62.
12. Rezaie AR, Esmon CT. Contribution of residue 192 in factor Xa to enzyme specificity and function. J Biol Chem 1995; 270: 16176-81.
13. Rezaie AR, Esmon CT. Molecular basis of residue 192 participation in determination of coagulation protease specificity. Eur J Biochem 1996; 242: 477-84.
14. Krem MM, Prasad S, Di Cera E. Ser(214) is crucial for substrate binding to serine proteases. J Biol Chem 2002; 277: 40260-4.
15. Neuenschwander PF, Morrissey JH. Alteration of the substrate and inhibitor specificities of blood coagulation factor VIIa: importance of amino acid residue K192. Biochemistry 1995; 34: 8701-7.
16. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
17. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
18. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
19. Di Cera E. Thrombin interactions. Chest 2003; 124: 11S-17S.
20. Liem RK, Scheraga HA. Mechanism of action of thrombin on fibrinogen. IV. Further mapping of the active sites of thrombin and trypsin. Arch Biochem Biophys 1974; 160: 333-9.
21. van Nispen JW, Hageman TC, Scheraga HA. Mechanism of action of thrombin on fibrinogen. The reaction of thrombin with fibrinogen-like peptides containing 11, 14, and 16 residues. Arch Biochem Biophys 1977; 182: 227-43.
22. Hageman TC, Scheraga HA. Mechanism of action of thrombin on fibrinogen. Reaction of the n-terminal CNBr fragment from the Bbeta chain of bovine fibrinogen with bovine thrombin. Arch Biochem Biophys 1977; 179: 506-17.
23. Doolittle RF. Fibrinogen and fibrin. Annu Rev Biochem 1984; 53: 195-229.
24. Mann KG, Heldebrant CM, Fass DN. Multiple active forms of thrombin. I. Partial resolution, differential activities, and sequential formation. J Biol Chem 1971; 246: 5994-6001.
25. Lundblad RL, Kingdon HS, Mann KG. Thrombin. Meth Enzymol 1976; 45: 156-76.
26. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-8.
27. Braun PJ, Dennis S, Hofsteenge J, Stone SR. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry 1988; 27: 6517-22.
28. Wallace A, Dennis S, Hofsteenge J, Stone SR. Contribution of the N-terminal region of hirudin to its interaction with thrombin. Biochemistry 1989; 28: 10079-84.
29. Betz A, Hofsteenge J, Stone SR. Interaction of the N-terminal region of hirudin with the active-site cleft of thrombin. Biochemistry 1992; 31: 4557-62.
30. Jackman MP, Parry MA, Hofsteenge J, Stone SR. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin. J Biol Chem 1992; 267: 15375-83.
31. Betz A, Hopkins PC, Le Bonniec BF, Stone SR. Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin. Biochem J 1994; 298: 507-10.
32. Stone SR, Betz A, Parry MA, Jackman MP, Hofsteenge J. Molecular basis for the inhibition of thrombin by hirudin. Adv Exp Med Biol 1993; 340: 35-49.
33. Bode W, Stubbs MT. Spatial structure of thrombin as a guide to its multiple sites of interaction. Semin Thromb Hemost 1993; 19: 321-33.
34. Stubbs MT, Bode W. A model for the specificity of fibrinogen cleavage by thrombin. Semin Thromb Hemost 1993; 19: 344-51.
35. Stubbs MT, Bode W. The clot thickens: clues provided by thrombin structure. Trends Biochem Sci 1995; 20: 23-8.
36. Jackson CM, Nemerson Y. Blood coagulation. Annu Rev Biochem 1980; 49: 765-811.
37. Mann KG. The assembly of blood clotting complexes on membranes. Trends Biochem Sci 1987; 12: 229-33.
38. Rosing J, Tans G, Govers Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83.
39. Nesheim ME, Tracy RP, Mann KG. 'Clotspeed', a mathematical simulation of the functional properties of prothrombinase. J Biol Chem 1984; 259: 1447-53.
40. Lu Y, Nelsestuen GL. The prothrombinase reaction: 'mechanism switching' between Michaelis-Menten and non-Michaelis-Menten behaviors. Biochemistry 1996; 35: 8201-9.
41. Pusey ML, Nelsestuen GL. The physical significance of Km in the prothrombinase reaction. Biochem Biophys Res Commun 1983; 114: 526-32.
42. Majumder R, Weinreb G, Zhai X, Lentz BR. Soluble phosphatidylserine triggers assembly in solution of a prothrombin-activating complex in the absence of a membrane surface. J Biol Chem 2002; 277: 29765-73.
43. Banerjee M, Majumder R, Weinreb G, Wang J, Lentz BR. Role of procoagulant lipids in human prothrombin activation. 2. Soluble phosphatidylserine upregulates and directs factor X(a) to appropriate peptide bonds in prothrombin. Biochemistry 2002; 41: 950-7.
44. Nesheim ME, Eid S, Mann KG. Assembly of the prothrombinase complex in the absence of prothrombin. J Biol Chem 1981; 256: 9874-82.
45. Walker RK, Krishnaswamy S. The influence of factor Va on the active site of factor Xa. J Biol Chem 1993; 268: 13920-9.
46. Buddai SK, Toulokhonova L, Bergum PW, Vlasuk GP, Krishnaswamy S. Nematode anticoagulant protein c2 reveals a site on factor Xa that is important for macromolecular substrate binding to human prothrombinase. J Biol Chem 2002; 277: 26689-98.
47. Lottenberg R, Hall JA, Pautler E, Zupan A, Christensen U, Jackson CM. The action of factor Xa on peptide p-nitroanilide substrates: substrate selectivity and examination of hydrolysis with different reaction conditions. Biochim Biophys Acta 1986; 874: 326-36.
48. Bianchini EP, Louvain VB, Marque PE, Juliano MA, Juliano L, Le Bonniec BF. Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates. J Biol Chem 2002; 277: 20527-34.
49. Mann KG, Elion J, Butkowski RJ, Downing M, Nesheim ME. Prothrombin. Meth Enzymol 1981; 80: 286-302.
50. Downing MR, Butkowski RJ, Clark MM, Mann KG. Human prothrombin activation. J Biol Chem 1975; 250: 8897-906.
51. Esmon CT, Jackson CM. The conversion of prothrombin to thrombin. III. The factor Xa-catalyzed activation of prothrombin. J Biol Chem 1974; 249: 7782-90.
52. Esmon CT, Owen WG, Jackson CM. The conversion of prothrombin to thrombin. V. The activation of prothrombin by factor Xa in the presence of phospholipid. J Biol Chem 1974; 249: 7798-807.
53. Krishnaswamy S, Church WR, Nesheim ME, Mann KG. Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem 1987; 262: 3291-9.
54. Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem 1986; 261: 8977-84.
55. Rosing J, Zwaal RF, Tans G. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation. J Biol Chem 1986; 261: 4224-8.
56. Walker RK, Krishnaswamy S. The activation of prothrombin by the prothrombinase complex. The contribution of the substrate-membrane interaction to catalysis. J Biol Chem 1994; 269: 27441-50.
57. Krishnaswamy S, Walker RK. Contribution of the prothrombin fragment 2 domain to the function of factor Va in the prothrombinase complex. Biochemistry 1997; 36: 3319-30.
58. Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-6.
59. Jacques SL, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PARI thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem 2000; 275: 40671-8.
60. Jencks WP. Catalysis in Chemistry and Enzymology, 1st edn. New York: Dover Publications Inc., 1987.
61. Boskovic DS, Krishnaswamy S. Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites. J Biol Chem 2000; 275: 38561-70.
62. Mihalyi E. Clotting of bovine fibrinogen. Kinetic analysis of the release of fibrinopeptides by thrombin and of the calcium uptake upon clotting at high fibrinogen concentrations. Biochemistry 1988; 27: 976-82.
63. Vijayalakshmi J, Padmanabhan KP, Mann KG, Tulinsky A. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin. Protein Sci 1994; 3: 2254-71.
64. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol 1993; 232: 947-66.
65. Martin PD, Malkowski MG, Box J, Esmon CT, Edwards BF. New insights into the regulation of the blood clotting cascade derived from the X-ray crystal structure of bovine meizothrombin des F1 in complex with PPACK. Structure 1997; 5: 1681-93.
66. Brufatto N, Nesheim ME. Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process. J Biol Chem 2003; 278: 6755-64.
67. Orcutt SJ, Pietropaolo C, Krishnaswamy S. Extended interactions with prothrombinase enforce affinity and specificity for its macromolecular substrate. J Biol Chem 2002; 277: 46191-6.
68. Boskovic DS, Troxler T, Krishnaswamy S. Active site-independent recognition of substrates and product by prothrombinase. A fluorescence resonance energy transfer study. J Biol Chem 2004; 279: 20786-93.
69. Betz A, Krishnaswamy S. Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex. J Biol Chem 1998; 273: 10709-18.
70. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 8: 3467-75.
71. Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol 1991; 221: 583-601.
72. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JWII. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249: 277-80.
73. Dharmawardana KR, Olson ST, Bock PE. Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments. J Biol Chem 1999; 274: 18635-43.
74. Dharmawardana KR, Bock PE. Demonstration of exosite I-dependent interactions of thrombin with human factor V and factor Va involving the factor Va heavy chain: analysis by affinity chromatography employing a novel method for active-site-selective immobilization of serine proteinases. Biochemistry 1998; 37: 13143-52.
75. Anderson PJ, Nesset A, Dharmawardana KR, Bock PE. Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation. J Biol Chem 2000; 275: 16435-42.
76. Chen L, Yang L, Rezaie AR. Proexosite-1 on prothrombin is a factor Va-dependent recognition site for the prothrombinase complex. J Biol Chem 2003; 278: 27564-9.
77. Boissel JP, Le Bonniec B, Rabiet MJ, Labie D, Elion J. Covalent structures of beta and gamma autolytic derivatives of human alpha-thrombin. J Biol Chem 1984; 259: 5691-7.
78. Hofsteenge J, Braun PJ, Stone SR. Enzymatic properties of proteolytic derivatives of human alpha-thrombin. Biochemistry 1988; 27: 2144-51.
79. Lewis SD, Brezniak DV, Fenton JW, Shafer JA. Catalytically competent human and bovine zeta-thrombin and chimeras generated from unfolded polypeptide chains. Protein Sci 1992; 1: 998-1006.
80. Greenspan NS, Di Cera E. Defining epitopes: it's not as easy as it seems. Nat Biotechnol 1999; 17: 936-7.
81. Esmon CT, Jackson CM. The conversion of prothrombin to thrombin. IV. The function of the fragment 2 region during activation in the presence of factor V. J Biol Chem 1974; 249: 7791-7.
82. Luckow EA, Lyons DA, Ridgeway TM, Esmon CT, Laue TM. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: analysis by analytical ultracentrifugation. Biochemistry 1989; 28: 2348-54.
83. Guinto ER, Esmon CT. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984; 259: 13986-92.
84. Church WR, Ouellette LA, Messier TL. Modulation of human prothrombin activation on phospholipid vesicles and platelets using monoclonal antibodies to prothrombin fragment 2. J Biol Chem 1991; 266: 8384-91.
85. Beck DO, Bukys MA, Singh LS, Szabo KA, Kalafatis M. The contribution of amino acid region ASP695-TYR698 of factor V to procofactor activation and factor Va function. J Biol Chem 2004; 279: 3084-95.
86. Betz A, Vlasuk GP, Bergum PW, Krishnaswamy S. Selective inhib ition of the prothrombinase complex: factor Va alters macromolecular recognition of a tick anticoagulant peptide mutant by factor Xa. Biochemistry 1997; 36: 181-91.
87. Krishnaswamy S, Vlasuk GP, Bergum PW. Assembly of the prothrombinase complex enhances the inhibition of bovine factor Xa by tick anticoagulant peptide. Biochemistry 1994; 33: 7897-907.
88. Church WR, Messier TL, Tucker MM, Mann KG. An inhibitory monoclonal antibody to factor X that blocks prothrombin activation but not prothrombinase enzyme assembly. Blood 1988; 72: 1911-21.
89. Wilkens M, Krishnaswamy S. The contribution of factor Xa to exosite-dependent substrate recognition by prothrombinase. J Biol Chem 2002; 277: 9366-74.
90. Baugh RJ, Dickinson CD, Ruf W, Krishnaswamy S. Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem 2000; 275: 28826-33.
91. Shobe J, Dickinson CD, Edgington TS, Ruf W. Macromolecular substrate affinity for the tissue factor-factor VIIa complex is independent of scissile bond docking. J Biol Chem 1999; 274: 24171-5.
92. Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF/VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997; 78: 401-5.
93. Rehemtulla A, Ruf W, Miles DJ, Edgington TS. The third Trp-Lys-Ser (WKS) tripeptide motif in tissue factor is associated with a function site. Biochem J 1992; 282: 737-40.
94. Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267: 22206-10.
95. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
96. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46: 103-12.
97. Iakhiaev A, Ruf W, Rao LV. The role of catalytic cleft and exosite residues of factor Vila for complex formation with tissue factor pathway inhibitor. Thromb Haemost 2001; 85: 458-63.
98. Bergum PW, Cruickshank A, Maki SL, Kelly CR, Ruf W, Vlasuk GP. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2 (rNAPc2). J Biol Chem 2001; 276: 10063-71.
99. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7.
100. Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE, Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem 1992; 267: 17006-11.
101. Aktimur A, Gabriel MA, Gailani D, Toomey JR. The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa. J Biol Chem 2003; 278: 7981-7.
102. Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271: 29023-8.
103. Gale AJ, Tsavaler A, Griffin JH. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem 2002; 277: 28836-40.
104. Friedrich U, Nicolaes GA, Villoutreix BO, Dahlback B. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J Biol Chem 2001; 276: 23105-8.
105. Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, Morser J, Light DR, Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-25.
106. Schneider M, Nagashima M, Knappe S, Zhao L, Morser J, Nesheim ME. Amino acid residues in the P6-P′3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation. J Biol Chem 2002; 277: 9944-51.
107. Rezaie AR, Yang L. Thrombomodulin allosterically modulates the activity of the anticoagulant thrombin. Proc Natl Acad Sci USA 2003; 100: 12051-6.
108. Ke SH, Tachias K, Lamba D, Bode W, Madison EL. Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. J Biol Chem 1997; 272: 1811-6.
109. Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol 2002; 22: 51-86.
110. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nature Rev Mol Cell Biol 2002; 3: 509-19.
111. Cornille F, Martin L, Lenoir C, Cussac D, Roques BP, Fournie-Zaluski MC. Cooperative exosite-dependent cleavage of synaptobrevin by tetanus toxin light chain. J Biol Chem 1997; 272: 3459-64.
112. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 1995; 80: 225-36.
113. Hunter T. Signaling - 2000 and beyond. Cell 2000; 100: 113-27.
114. Stanley TB, Wu SM, Houben RJ, Mutucumarana VP, Stafford DW. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry 1998; 37: 13262-8.
115. Brandstetter H, Kuhne A, Bode W, Huber R, von der Saal W, Wirthensohn K, Engh RA. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996; 271: 29988-92.